Reliable predictions across scales will transform drug development.
We envision the ability to accurately predict the effects of change by reading the results of millions of natural experiments.
Natural experiments
Nature conducts millions of silent experiments every time a new life is conceived: changes on a molecular scale, that have effects on a whole person. Multiscale Labs has the logistics and experience to read the results of these experiments.
Foundations matter
Drug target discovery - and validation - is fundamentally a prediction from molecule to organism. It fails because we don’t have the right data. Multiscale will make reliable predictions by focusing on robust experimental signals.
Quantified certainty
Biological systems arose by chance from chaos. We can see the intractable complexity of these systems. At Multiscale, we leverage the capability of AI to recognise complex patterns, but we quantify the certainty in every predicition we make. We will make discoveries that transform medicine, because we can prove they are robust.
Core Team
World-leading clinicians, biologists and computational scientists
Kenneth Baillie
Chief Executive Officer
Kenneth Baillie, FRSE FMedSci, is a visionary leader who bridges the gap between genomic discovery and clinical breakthroughs.
When every genomics group in the world was spending billions to solve the same problem, Baillie’s clinical and scientific insight put his team ahead: he was first to discover 75% of Covid-19 host genes. His genetics and computational biology work led directly to the discovery of baricitinib as an effective COVID-19 treatment - the first time in history that a host genetic discovery has led to an effective new drug treatment for any infectious disease.
He has secured over £100 million in career funding, is in the top 1% of highly-cited researchers worldwide. He is leveraging his unique expertise in genomics, biological systems, and medicine to lead Multiscale Labs to transform patients’ lives.
Konrad Rawlik
Chief Technical Officer
Konrad Rawlik, PhD, is a 10x quantitative methodology innovator.
Dr Rawlik won the biggest race in the history of genomics. The unprecedented data release from UK Biobank sparked a global contest to discover genetic mechanisms of hundreds of human diseases. Rawlik devised and implemented a method to conduct genome-wide analyses faster than any other group in the world.
Dr. Rawlik’s research bridges theoretical machine learning and real-world genomic analysis. As Multiscale’s Chief Technical Officer, he leads the development of our AI-driven biological modeling platform. His rare combination of deep technical expertise and proven business leadership makes him ideally suited to transform our vision of a comprehensive, cross-species biological model into reality.
Jonathan Millar
Chief Medical Officer
Jonathan Millar, MD PhD, brings a powerful combination of clinical expertise and computational innovation to his role as Multiscale’s Chief Medical Officer. As a Senior Research Fellow at the University of Edinburgh and Consultant in Intensive Care Medicine, he has pursued the integration of AI and omics technologies into therapeutic discovery and clinical trials.
Dr. Millar’s leadership of several international studies, demonstrates his ability to orchestrate complex, large-scale clinical research programs. His extensive work building global research networks across North America, Europe, Asia, and Australasia positions him uniquely at the intersection of international scientific collaboration and technological innovation.
At Multiscale, Dr. Millar harnesses his distinctive blend of clinical insight and computational expertise to drive the development of AI-powered solutions that decode biological complexity across species and scales.
Mirella Lapata
Head of AI Research
Mirella Lapata, FRSE, is a global deep learning pioneer. She is consistently ranked in the top 5 worldwide in Natural Language Processing. She pioneered deep learning for text generation, replacing rigid pipelines with trainable models. Her breakthroughs in planning-based methods reshaped the field. Lapata has won numerous awards, including a Turing fellowship, and the 2025 Ada Lovelace Award in Computer Science, the British Computer Society Karen Spärck Jones Award and election to Academia Europaea.
Her founding of the Edinburgh Laboratory for Integrated Artificial Intelligence (ELIAI) and strategic collaborations with tech leaders like Google DeepMind and Amazon demonstrate her ability to translate cutting-edge research into practical applications.
At Multiscale, Professor Lapata’s pioneering work in AI and language understanding is instrumental in decoding complex biological data across diverse life forms. Her expertise in developing sophisticated AI systems that can interpret and generate complex information is helping revolutionise our understanding of biological systems, from microscopic organisms to human disease.
Work with us
We are building the best team in the world to solve one of the biggest problems facing humanity. Our values matter to us - they are what drives everyone in the company:
Humility
Our foundation is humility in the face of the intractable complexity of human biology. We recognise what we cannot know, we get the data we need, and we test our theories. Every single one.
No bullshit
We do what we say we will do. It is why we achieve what we say we will achieve.
Impact
We are not messing around. We’re here to make a massive positive impact on medicine. Come and join us.
Collaborate
Get in touch with our team